Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Amit Sanyal, MD: A Clinician’s Perspective

Oct

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Amit Sanyal, MD: A Clinician’s Perspective

HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy

FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC

FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer

Cancer Statistics 2026: Incidence, Mortality, Survival, and Disparities in U.S. Oncology

FDA Approves First-Line Pirtobrutinib for CLL-SLL